Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

Two of the most notable examples of this in recent years are Actavis ... US firm choosing to launch its first-in-class cystic fibrosis drug Kalydeco around the world without a big pharma partner.

After hours: January 30 at 4:53:00 PM EST Loading Chart for CRNX ...

Companies that have grown profits and net profit margins over the past 12 months ...

After hours: January 30 at 4:34:40 PM EST Loading Chart for SNDX ...

Other cases in the US include the FTC's pursuit of AbbVie subsidiary Solvay and Actavis unit Watson on testosterone replacement therapy product Androgel, while in the EU Servier, Johnson & Johnson ...

We assign Teva a Morningstar Uncertainty Rating of High, which largely reflects our quantitative analysis of the firm, based on the return ranges used by our star rating system, as well as our ...

semiconductors and pharmaceuticals "to return production of these essential goods to the United States of America." "They left us, and they went to Taiwan, which is about 98% of the chip business ...

found that pharmaceutical drugs are the third largest cause of death in our country, after heart attack and cancer. They're not making us healthier," Kennedy said.